Origen Financial, Inc. (ORGN: OTC Pink Limited) | Origen

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Origen Financial, Inc. (ORGN: OTC Pink Limited) | Origen Financial Announces First Quarter 2013 Results Origen Financial Announces First Quarter 2013 Results

Origen Financial Announces First Quarter 2013 Results

PR Newswire

SOUTHFIELD, Mich. , May 14, 2013 /PRNewswire/ -- Origen Financial, Inc. (Pink Sheets: ORGN) ("Origen" or the "Company"), a real estate investment trust that manages residual interests in securitized manufactured housing loan portfolios, today announced a net loss of $1.9 million , or $0.07 per common share, for the quarter ended March 31, 2013, as compared to net income, as restated, of $3.9 million , or $0.15 per common share for the first quarter of 2012.  The first quarter 2012 net income was the result of the termination of interest rate swap transactions which resulted in gains of approximately $6.2 million .  Absent such gains, Origen's first quarter 2012 results would have reflected a net loss of $2.4 million , or $0.09 per common share.

On May 14, 2013 , Origen's Board of Directors declared a common stock dividend of $0.09 per share to be paid to holders of Origen's common stock of record on May 27 , 2013.  The dividend will be paid on June 3, 2013 and will approximate $2.3 million . The cash dividend will represent a return of capital.

For the first quarter 2013, net interest income before loan losses and impairment decreased by approximately 15 percent to $4.0 million from $4.7 million for the first quarter 2012.  Non-interest income for the first quarter 2013 totaled $133,000 versus $7.3 million for first quarter 2012 reflecting the prior year gain on termination of interest rate swap transactions. The first quarter 2013 provision for loan losses was $3.3 million versus $5.2 million for the prior year quarter, a decrease of approximately 37 percent.  The decrease in provision for loan losses reflects the declining balances of the Company's static loan portfolio and improvements in recoveries on dispositions of foreclosed and repossessed properties.

Non-interest expenses, including $1.8 million of loan servicing expenses, were $2.6 million for the first quarter 2013, as compared to $2.9 million , including $2.1 million of loan servicing expense, for the year ago quarter, a decrease of approximately 10 percent.  Loan servicing expenses constituted approximately 69 percent and 72 percent of total non-interest expenses, respectively, for first quarter 2013 and 2012.

Earnings Call and Webcast

A conference call has been scheduled for Wednesday, May 15, 2013 , at 11:00 a.m. Eastern Time to discuss first quarter 2013 results and current operations.  The call may be accessed by dialing 888-438-5525 or 719-325-2420.  A replay will be available through May 22, 2013 by dialing 877-870-5176 or 858-384-5517 pass code 5399689. 

Forward-Looking Statements

This press release contains various "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, and Origen intends that such forward-looking statements will be subject to the safe harbors created thereby. The words "will," "may," "could," "expect," "anticipate," "believes," "intends," "should," "plans," "estimates," "approximate" and similar expressions identify these forward-looking statements. These forward-looking statements reflect Origen's current views with respect to future events and financial performance, but involve known and unknown risks and uncertainties, both general and specific to the matters discussed in this press release. These risks and uncertainties may cause Origen's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the foregoing assumptions and those risks referenced under the headings entitled "Factors That May Affect Future Results" or "Risk Factors" contained in Origen's filings. The forward-looking statements contained in this press release speak only as of the date hereof and Origen expressly disclaims any obligation to provide public updates, revisions or amendments to any forward- looking statements made herein to reflect changes in Origen's expectations or future events.

About Origen Financial, Inc.

Origen is an internally managed and internally advised company that has elected to be taxed as a real estate investment trust. Origen is based in Southfield, Michigan .

For more information about Origen, please visit http://www.origenfinancial.com .

Financial Tables Follow…

ORIGEN FINANCIAL, INC.

CONSOLIDATED BALANCE SHEETS

(Dollars in thousands)









ASSETS






(Unaudited)




March 31,


December 31,


2013


2012

Assets




     Cash and Equivalents

$                   1,544


$                      826

     Restricted Cash

10,468


11,110

     Investment Securities

1,379


1,442

     Loans Receivable

522,389


543,420

     Furniture, Fixtures and Equipment, Net

48


33

     Repossessed Houses

2,437


2,180

     Other Assets

4,148


4,233

Total Assets

$               542,413


$               563,244





LIABILITIES AND STOCKHOLDERS' EQUITY





Liabilities




     Securitization Financing

475,349


491,720

     Derivative Liabilities

35,537


37,454

     Other Liabilities

10,400


10,935

Total Liabilities

521,286


540,109





Equity

21,127


23,135





Total Liabilities and Equity

$               542,413


$               563,244

ORIGEN FINANCIAL, INC.

CONSOLIDATED STATEMENT OF EARNINGS

(Dollars in thousands, except for share data)











(Unaudited)


Three Months Ended


March 31,


2013


2012 (as restated)

Interest Income




   Total Interest Income

$              12,540


$                     14,501

   Total Interest Expense

8,580


9,786

Net Interest Income Before Loan Losses and Impairment

3,960


4,715

   Provision for Loan Losses

3,312


5,154

Net Interest Income (Loss) After Loan Losses and Impairment

648


(439)

Non-interest Income (Loss)




   Realized Gain on Derivative

-


6,278

   Other

133


982

Total Non-interest Income

133


7,260

Non-interest Expenses




   Total Personnel

356


331

   Total Loan Origination & Servicing

1,790


2,069

   State Taxes

73


86

   Other Operating

408


453

Total Non-interest Expenses

2,627


2,939

Net Income (Loss) Before Income Taxes

(1,846)


3,882

   Income Tax Expense

7


18

   Net Income (Loss)

$               (1,853)


$                        3,864





Weighted Average Common Shares Outstanding, Basic and Diluted

25,926,149


25,926,149





   Net Income (Loss) Per Common Share

$                 (0.07)


$                          0.15

SOURCE Origen Financial, Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 9

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 123

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 52

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 422

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 175

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 104

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 0

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 432

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 287

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 557

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading

Top 5 Most Recently Viewed Articles

NKGen Biotech to Present Innovative Research at Global Congress

Updated Category News Views 157

NKGen Biotech's Exciting Announcement on Upcoming Presentation NKGen Biotech Inc. (NASDAQ: NKGN), a pioneering clinical-stage biotechnology firm dedicated to developing cutting-edge autologous and allogeneic natural killer cell therapies, has recently shared some thrilling news regarding their participation in an international event. Highlighting Neurodegenerative...

Continue Reading
Celebrating Case Managers: A Call to Action for 2025

Updated Category News Views 522

Recognizing the Contribution of Case Managers in 2025 Case managers have proven time and again to be essential contributors to the health and human services spectrum. In 2025, the two prominent organizations in the case management field—the American Case Management Association (ACMA) and the Commission for Case Manager Certification (CCMC)—have once again partnered to...

Continue Reading
Faruqi & Faruqi Investigates Ford Investor Claims

Updated Category News Views 92

Back in 2024, Faruqi & Faruqi took aim at Ford Motor Company (NYSE: F), investigating claims from investors who’d racked up losses over $100,000. They were diving deep into the financial mess at Ford—a colossal vehicle manufacturer that found itself knee-deep in allegations of breaching federal securities laws. The chatter was all about how quality assurance failures...

Continue Reading
Entourage Health Announces Going-Private Arrangement Plan

Updated Category News Views 236

Entourage Health Corp. Takes a Bold Step Toward Going-Private Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) has officially entered into a significant arrangement agreement with 1001007762 Ontario Inc. and 2437653 Ontario Inc. This strategic move, a statutory plan under the Business Corporations Act (Ontario), sees the Purchaser agreeing to acquire all common shares...

Continue Reading
A&W Revenue Royalties Income Fund Q3 2024 Results Review

Updated Category News Views 183

A&W Revenue Royalties Income Fund Q3 2024 Financial Overview TRADING SYMBOL: TSX: AW.UN A&W Revenue Royalties Income Fund has reported encouraging results for the third quarter ending this year. The quarterly performance reflects steady royalty income growth and strategic developments that promise an exciting future. Royalty Income Performance In the third quarter of...

Continue Reading